IOBT (IO Biotech, Inc.) Stock Market Reviews

crown

search

Read and share opinions on IOBT (IO Biotech, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

IOBT

IO Biotech, Inc.

clarify Biotechnology

bookmark Healthcare

public Denmark

Sell Neutral Buy

Latest News

IO Biotech Announces Participation in Upcoming Investor Conferences
Nov 12, 2025
IO Biotech Faces Setback as FDA Opposes Cylembio BLA Submission, Morgan Stanley Says
Sep 30, 2025
IO Biotech Provides Update Following Pre-BLA Meeting with FDA
Sep 29, 2025
IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025
Sep 23, 2025
IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's What You Should Know
Sep 3, 2025
H.C. Wainwright Reiterates Buy Rating on IO Biotech, Keeps PT at $14
Aug 26, 2025
IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
Aug 10, 2025
IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference
May 20, 2025
IO Biotech price target raised to $14 from $12 at H.C. Wainwright
May 15, 2025

Reviews